Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.
Immunol Rev. 2011 Jul;242(1):247-57. doi: 10.1111/j.1600-065X.2011.01028.x.
In the century since Paul Portier and Charles Richet described their landmark findings of severe fatal reactions in dogs re-exposed to venom after vaccination with sea anemone venom, treatment for anaphylaxis continues to evolve. The incidence of anaphylaxis continues to be difficult to measure. Underreporting due to patients not seeking medical care as well as failure to identify anaphylaxis affects our understanding of the magnitude of the disease. Treatment with intramuscular epinephrine continues to be the recommended first-line therapy, although studies indicate that education of both the patients and the medical community is needed. Adverse food reactions continue to be the leading cause of anaphylaxis presenting for emergency care. Current therapy for food-induced anaphylaxis is built on the foundation of strict dietary avoidance, rapid access to injectable epinephrine, and education to recognize signs and symptoms of anaphylaxis. Investigation into therapy with oral and sublingual immunotherapy as well as other modalities holds hope for improved treatment of food-induced anaphylaxis.
自 Paul Portier 和 Charles Richet 描述了他们的里程碑式发现以来,已有一个世纪,即在被海葵毒液疫苗接种后再次暴露于毒液的狗中出现严重致命反应,过敏反应的治疗仍在不断发展。过敏反应的发生率仍然难以衡量。由于患者没有寻求医疗护理以及未能识别过敏反应,导致报告不足,这影响了我们对疾病严重程度的理解。肌肉内肾上腺素治疗仍然是推荐的一线治疗方法,尽管研究表明需要对患者和医疗社区进行教育。食物不良反应仍然是因过敏反应而紧急就医的主要原因。目前针对食物引起的过敏反应的治疗是基于严格的饮食回避、快速获得可注射肾上腺素以及教育以识别过敏反应的迹象和症状的基础上建立的。对口服和舌下免疫疗法以及其他方式的治疗的研究为改善食物引起的过敏反应的治疗带来了希望。